Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease

被引：43

作者：

Teshima, Takanori ^{[1
]}

Nagafuji, Koji ^{[2
]}

Henzan, Hideho ^{[3
]}

Miyamura, Koichi ^{[4
]}

Takase, Ken ^{[3
]}

Hidaka, Michihiro ^{[5
]}

Miyamoto, Toshihiro ^{[1
,2
]}

Takenaka, Katsuto ^{[2
]}

Akashi, Koichi ^{[1
,2
]}

Harada, Mine ^{[2
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Ctr Cellular & Mol Med, Higashi Ku, Fukuoka 8128582, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Higashi Ku, Fukuoka 8128582, Japan

[3] Hamanomachi Gen Hosp, Dept Hematol, Fukuoka, Japan

[4] Japanese Red Cross Nagoya Daiichi Hosp, Dept Hematol, Nagoya, Aichi, Japan

[5] Natl Hosp Org, Kumamoto Med Ctr, Dept Internal Med, Kumamoto, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2009年 / 90卷 / 02期

关键词：

Rituximab; Chronic GVHD; Corticosteroids; Allogeneic transplantation; ANTI-CD20; MONOCLONAL-ANTIBODY; CONSENSUS DEVELOPMENT PROJECT; BONE-MARROW-TRANSPLANTATION; WORKING GROUP-REPORT; MINOR HISTOCOMPATIBILITY ANTIGEN; STEM-CELL TRANSPLANTATION; CLINICAL-TRIALS; B-CELLS; CHRONIC GVHD; THERAPY;

D O I：

10.1007/s12185-009-0370-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We prospectively evaluated the safety and efficacy of the anti-CD20 chimeric monoclonal antibody rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Seven patients were treated with 375 mg/m(2) rituximab weekly for 4 consecutive weeks. Rituximab was well tolerated with no severe toxicity observed during treatment. At 1 year, 3 patients showed a partial response to rituximab therapy, 3 had stable disease, and 1 had progressive disease. Rituximab allowed a reduction in the dose of steroids in 4 patients. Responsive manifestations included mild to moderate skin and oral lesions, and immune hemolytic anemia, and thrombocytopenia. Severe manifestations involving the skin, fascia, and eye did not respond to treatment. These observations suggest that rituximab therapy may be effective for select patients with corticosteroid-refractory chronic GVHD that is not advanced.

引用

页码：253 / 260

页数：8

共 50 条

[31] Ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis of 95 patients treated at multiple medical centers
Zeiser, R.
Burchert, A.
Lengerke, C.
Verbeek, M.
Maas-Bauer, K.
Metzelder, S.
Spoerl, S.
Ditschkowski, M.
Ecsedi, M.
Sockel, K.
Ayuk, F.
Ajib, S.
de Fontbrune, Sicre F.
Na, I. -K
Penter, L.
Holtick, U.
Wolf, D.
Schuler, E.
Meyer, E.
Apostolova, P.
Bertz, H.
Marks, R.
Luebbert, M.
Waesch, R.
Scheid, C.
Ordemann, R.
Bug, G.
Kobbe, G.
Negrin, R.
Brune, M.
Spyridonidis, A.
Schmitt-Graeff, A.
van der Velden, W.
Huls, G.
Grigoleit, G. U.
Kuball, J.
Blazar, B. R.
Arnold, R.
Kroeger, N.
Passweg, J.
Halter, J.
Socie, G.
Beelen, D.
Peschel, C.
Neubauer, A.
Finke, J.
Duyster, J.
von Bubnoff, N.
Oncology Research and Treatment, 2015, 38 : 43 - 44
[32] Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R Zeiser
A Burchert
C Lengerke
M Verbeek
K Maas-Bauer
S K Metzelder
S Spoerl
M Ditschkowski
M Ecsedi
K Sockel
F Ayuk
S Ajib
F S de Fontbrune
I-K Na
L Penter
U Holtick
D Wolf
E Schuler
E Meyer
P Apostolova
H Bertz
R Marks
M Lübbert
R Wäsch
C Scheid
F Stölzel
R Ordemann
G Bug
G Kobbe
R Negrin
M Brune
A Spyridonidis
A Schmitt-Gräff
W van der Velden
G Huls
S Mielke
G U Grigoleit
J Kuball
R Flynn
G Ihorst
J Du
B R Blazar
R Arnold
N Kröger
J Passweg
J Halter
G Socié
D Beelen
C Peschel
A Neubauer
Leukemia, 2015, 29 : 2062 - 2068
[33] Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab
von Bonin, Malte
Oelschlaegel, Uta
Radke, Joergen
Stewart, Michelle
Ehninger, Gerhard
Bornhauser, Martin
Platzbecker, Uwe
TRANSPLANTATION, 2008, 86 (06) : 875 - 879
[34] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
M Okamoto
A Okano
S Akamatsu
E Ashihara
T Inaba
H Takenaka
N Katoh
S Kishimoto
C Shimazaki
Leukemia, 2006, 20 : 172 - 173
[35] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
Okamoto, M
Okano, A
Akamatsu, S
Ashihara, E
Inaba, T
Takenaka, H
Katoh, N
Kishimoto, S
Shimazaki, C
LEUKEMIA, 2006, 20 (01) : 172 - 173
[36] Improving treatment of refractory chronic extensive graft-versus-host disease
Elez, M.
Stamatovic, D.
Tukic, L.
Tarabar, O.
Balint, B.
Skuletic, V.
Tasic, O.
Simic, L.
Malesevic, M.
BONE MARROW TRANSPLANTATION, 2008, 41 : S413 - S414
[37] Rituximab for prevention and treatment of graft-versus-host disease
Kharfan-Dabaja, Mohamed A.
Cutler, Corey S.
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (05) : 578 - 585
[38] Rituximab for prevention and treatment of graft-versus-host disease
Mohamed A. Kharfan-Dabaja
Corey S. Cutler
International Journal of Hematology, 2011, 93 : 578 - 585
[39] Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib
Zeiser, Robert
Burchert, Andreas
Lengerke, Claudia
Verbeek, Mareike
Maas-Bauer, Kristina
Metzelder, Stephan
Spoerl, Silvia
Ditschkowski, Markus
Ecsedi, Matyas
Sockel, Katja
Ayuk, Francis
Salem, Ajib
de Fontbrune, Flore Sicre
Na, Il-Kang
Livius, Penter
Holtick, Udo
Wolf, Dominik
Schuler, Esther
Meyer, Everett
Apostolova, Petya
Bertz, Hartmut
Marks, Reinhard
Lubbert, Michael
Wasch, Ralph
Scheid, Christof
Stolzel, Friedrich
Ordemann, Rainer
Bug, Gesine
Kobbe, Guido
Shah, Omid
Negrin, Robert S.
Brune, Mats
Spyridonidis, Alexandros
Schmitt-Graeff, Annette
van der Velden, Walter J. F. M.
Huls, Gerwin
Mielke, Stephan
Grigoleit, Goetz Ulrich
Kuball, Jurgen
Flynn, Ryan P.
Ihorst, Gabriele
Du, Jing
Blazar, Bruce R.
Arnold, Renate
Kroger, Nicolaus
Passweg, Jakob R.
Halter, Joerg
Socie, Gerard
Beelen, Dietrich W.
Peschel, Christian
BLOOD, 2016, 128 (22)
[40] A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease
Bhatt, Vijaya Raj
Shostrom, Valerie K.
Choe, Hannah K.
Hamilton, Betty K.
Gundabolu, Krishna
Maness, Lori J.
Kumar, Virender
Mahato, Ram I.
Smith, Lynette M.
Nishihori, Taiga
Lee, Stephanie J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)

← 1 2 3 4 5 →